We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CAMCEVI

News List

Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States prnasia
March 05, 2021
Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with Intas Pharmaceuticals for the US commercialization of Foresee's novel FP-001 program, Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use ...
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China prnasia
November 18, 2020
Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with GenScience Pharmaceuticals - a wholly-owned subsidiary of Changchun High-Tech Industry (Group) Co., Ltd. - for the commercialization of Foresee's novel FP-001..
Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA prnasia
October 10, 2020
Foresee Pharmaceuticals Co., Ltd. announced that the 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI™ 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the U.S. Food and Drug ...